July 10, 2020
GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021
Media
July 07, 2020
GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment
July 03, 2020
Vicore Pharma has completed a directed share issue of SEK 185 million
July 02, 2020
Vicore Pharma intends to carry out a directed share issue
July 02, 2020
GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020
July 02, 2020
Invitation to attend a teleconference on July 2, 1.30 pm CET – DTx US commercialization plan
July 02, 2020
Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance
July 01, 2020
Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
June 30, 2020
Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO
June 30, 2020
Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal